NCI-H2452人間皮瘤細(xì)胞
具體成交價(jià)以合同協(xié)議為準(zhǔn)
- 公司名稱 上海富雨生物科技有限公司
- 品牌
- 型號(hào)
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2025/2/11 17:34:13
- 訪問(wèn)次數(shù) 103
聯(lián)系方式：陳壽彬18956075901 查看聯(lián)系方式
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息，謝謝!
人間皮瘤細(xì)胞NCI-H2452
| 種屬 | 人 |
| 別稱 | H2452;H-2452;NCIH2452 |
| 組織來(lái)源 | 肺 |
| 疾病 | 間皮瘤 |
| 傳代比例/細(xì)胞消化 | 1:2傳代，消化2-3分鐘 |
| 培養(yǎng)基配置 | RPMI1640培養(yǎng)基；10%胎牛血清；1%雙抗 |
| 簡(jiǎn)介 | 該細(xì)胞是1990年11月由一名患有間皮瘤的非吸煙者建立的。 |
| 形態(tài) | 上皮細(xì)胞樣 |
| 生長(zhǎng)特征 | 貼壁生長(zhǎng) |
| 倍增時(shí)間 | ~48h |
| STR | Amelogenin:X,Y CSF1P0:11,12 D13S317:12 D16S539:11,13 D5S818:11,12 D7S820:9,11 THO1:6,9.3 TPOX:8,11 vWA:17,18 |
| 保藏機(jī)構(gòu) | ATCC;CRL-5946 |
immunotherapy and can confer profound resistance. Yet, the tumor-promoting environment - due to its enormous plasticity - also delivers the best opportunities for adjuvant therapy aiming at recruiting, priming and sustaining anti-tumor cytotoxicity. While the tumor environment as an entity is increasingly well understood, current interventions are still broad and often systemic. In contrast, tumors grow in a highly compartmentalized environment which includes the
采購(gòu)中心
化工儀器網(wǎng)